New parenteral formulation for the management of postoperative pain

最近的研究强调了COX 2抑制剂作为阿片类药物的替代品用于术后疼痛管理的价值，特别是塞来昔布的使用。由于其非常低的水溶性，西乐葆仅以片剂形式提供，当片剂制剂不能给药时，排除了其在手术期间和手术后立即使用。Altus Formulation是一家制药公司，专门从事创新药物输送系统的开发。在他们的各种输送平台中，SmartCelle技术能够实现高度不溶性药物的肠胃外输送。在我们机构进行的先前研究强调了该技术的潜力，证明了新型可溶性制剂在足底切口术后疼痛模型中的镇痛潜力。该项目旨在通过确定胶束制剂的有效剂量50和评价塞来昔布与CB 2受体激动剂Hu-308联合给药的协同潜力，围绕新型塞来昔布可溶性制剂的开发和验证开展临床前工作。

Recent studies have highlighted the value of COX2 inhibitors as alternatives to opioids for the management of postoperative pain and, in particular, the use of Celecoxib. Due to its very low water solubility Celebrex is only available in tablet, precluding its use during and immediately after surgery when tablet formulations cannot be administered. Altus Formulation is a pharmaceutical company specialized in the development of innovative drug delivery systems. Among their various delivery platforms, the SmartCelle technology enables the parenteral delivery of highly insoluble drugs. A previous study, conducted at our facility highlighted the potential of the technology, demonstrating the analgesic potential of the novel soluble formulation in the plantar incision postoperative pain model. This project aims to pursue the preclinical work surrounding the development and the validation of the novel Celecoxib soluble formulation by determining the effective dose 50 of the micellar formulation and evaluating the synergetic potential of the co-administration of Celecoxib and the CB2 receptor agonist Hu-308.